1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Appili Therapeutics Inc.
  6. News
  7. Summary
    APLI   CA03783R1073

APPILI THERAPEUTICS INC.

(APLI)
  Report
Delayed Quote. Delayed Toronto Stock Exchange - 05/27 02:03:51 pm
0.08 CAD   +6.67%
05/26Appili Therapeutics Compleres Public Offering of $4.5 Million
MT
05/18Appili Therapeutics Drops Near 16% as Prices $4.5 Million Offering
MT
05/18Appili Therapeutics Prices $4.5 Million Offering
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Appili Therapeutics - Press Release Correction

12/24/2021 | 03:50am EDT

HALIFAX, Nova Scotia - Appili Therapeutics Inc. (TSX: APLI) (the 'Company' or 'Appili') announced a correction to its press release entitled 'Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners' which was issued on December 22, 2021 (the 'Initial Press Release').

The Initial Press Release incorrectly stated that Lind had agreed to a standstill period expiring on March 18, 2021. The correct expiry date for the standstill period is March 18, 2022. This correction does not change any other information reported in the Initial Press Release.

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Contact:

Media

Danielle Raabe

APCO Worldwide

T: 1-646-717-9915

E: DRaabe@apcoworldwide.com

Investor

Stephane Paquette

Vice President

Corporate Development

Appili Therapeutics

E: Info@AppiliTherapeutics.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about APPILI THERAPEUTICS INC.
05/26Appili Therapeutics Compleres Public Offering of $4.5 Million
MT
05/18Appili Therapeutics Drops Near 16% as Prices $4.5 Million Offering
MT
05/18Appili Therapeutics Prices $4.5 Million Offering
MT
05/18IIROC Trade Resumption - APLI
AQ
05/18Appili Therapeutics Announces Overnight Marketed Equity Offering
AQ
05/17IIROC Trading Halt - APLI
AQ
05/17Appili Therapeutics Details Overnight Marketed Equity Offering
MT
05/17APPILI THERAPEUTICS BRIIEF : Details Overnight Marketed Equity Offering
MT
04/27Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Confe..
BU
04/13Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneo..
MT
More news
Financials
Sales 2022 0,83 M 0,65 M 0,65 M
Net income 2022 -28,5 M -22,4 M -22,4 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 9,70 M 7,61 M 7,61 M
Capi. / Sales 2022 11,8x
Capi. / Sales 2023 45,1x
Nbr of Employees 15
Free-Float 78,8%
Chart APPILI THERAPEUTICS INC.
Duration : Period :
Appili Therapeutics Inc. Technical Analysis Chart | APLI | CA03783R1073 | MarketScreener
Technical analysis trends APPILI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,08 CAD
Average target price 0,25 CAD
Spread / Average Target 213%
Managers and Directors
Armand L. Balboni Chief Executive Officer & Director
Kenneth G. Howling Chief Financial Officer
Ian C. Mortimer Chairman
Yoav Golan Chief Medical Officer
Theresa Matkovits Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APPILI THERAPEUTICS INC.-30.43%8
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958